Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Gaël S. Roth, Cindy Neuzillet, Matthieu Sarabi, et al.
European Journal of Cancer (2022) Vol. 179, pp. 1-14
Open Access | Times Cited: 18

Showing 18 citing articles:

Cisplatin in Liver Cancer Therapy
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 41
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
Gaël S. Roth, Loïc Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114000-114000
Open Access | Times Cited: 8
Durvalumab: A Review in Advanced Biliary Tract Cancer
Simon Fung, Yahiya Y. Syed
Targeted Oncology (2023) Vol. 18, Iss. 6, pp. 965-972
Open Access | Times Cited: 12
Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25
Hyeseon Yun, Hong‐Rae Jeong, Do Yeon Kim, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 3
Open Access | Times Cited: 4
First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
Ziqi Ye, Y. Zhang, Jie Chen, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110344-110344
Closed Access | Times Cited: 9
Recent Updates on Local Ablative Therapy Combined with Chemotherapy for Extrahepatic Cholangiocarcinoma: Photodynamic Therapy and Radiofrequency Ablation
Tadahisa Inoue, Masashi Yoneda
Current Oncology (2023) Vol. 30, Iss. 2, pp. 2159-2168
Open Access | Times Cited: 8
Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
Yanfang Zhang, Xiaoting Wang, Yinyan Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Endoscopic intraductal radiofrequency ablation for extrahepatic cholangiocarcinoma: An update (2023)
Tadahisa Inoue, Masashi Yoneda
World Journal of Gastrointestinal Endoscopy (2023) Vol. 15, Iss. 6, pp. 440-446
Open Access | Times Cited: 4
Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies
Mar Ros-Buxó, Ezequiel Mauro, Tamara Saurí, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3615-3629
Open Access | Times Cited: 1
Preoperative controlling nutritional status (CONUT) score is an independent prognostic factor in cholangiocarcinoma patients treated with hepatectomy
Attapol Titapun, Aumkhae Sookprasert, Yanin Sripanuskul, et al.
Heliyon (2023) Vol. 9, Iss. 10, pp. e20473-e20473
Open Access | Times Cited: 3
Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
Qiuping Liu, Jie Tang, Yizhang Chen, et al.
JHEP Reports (2023) Vol. 5, Iss. 7, pp. 100763-100763
Open Access | Times Cited: 2
Establishment and validation of a nomogram model for preoperative prediction of the risk of cholangiocarcinoma with perineural invasion.
Maobing Wang, Zhaowei Sun, Qinlei Wang, et al.
PubMed (2023) Vol. 13, Iss. 11, pp. 5082-5093
Closed Access | Times Cited: 2
Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances
Dongxu Wang, Hui Liu, Jin-Cheng Tian, et al.
International Journal of Surgery (2024)
Open Access
MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5
Da Wang, Junsheng Chen, Guanhua Wu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access
Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin/gemcitabine: a systematic review and meta-analysis
Antonia Digklia, Dirk Arnold, Ioannis A. Voutsadakis
ESMO Gastrointestinal Oncology (2024) Vol. 4, pp. 100055-100055
Open Access
Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications
Maria De Bonis, Francesco Mannavola, Lisa Salvatore, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 8, pp. 7113-7120
Open Access | Times Cited: 1
Ivosidénib pour le traitement des cholangiocarcinomes avec une mutation IDH1 R132 préalablement traités
Tarik Rabehi, Stanislas Quesada
Bulletin du Cancer (2023) Vol. 110, Iss. 12, pp. 1230-1231
Closed Access | Times Cited: 1
Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications
Maria De Bonis, Francesco Mannavola, Lisa Salvatore, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top